We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-13.19%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.78B
AUM Growth
+$18.3M
Cap. Flow
+$443M
Cap. Flow %
15.93%
Top 10 Hldgs %
42.27%
Holding
179
New
61
Increased
32
Reduced
13
Closed
19

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$37.6M
2
UNH icon
UnitedHealth
UNH
+$37.4M
3
UTHR icon
United Therapeutics
UTHR
+$29.3M
4
MRK icon
Merck
MRK
+$27.6M
5
A icon
Agilent Technologies
A
+$24.1M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$27.7M
2
CELG
Celgene Corp
CELG
+$26.8M
3
CTRX
CATAMARAN CORP COM STK (CDA)
CTRX
+$26.5M
4
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$23.7M
5
ACOR
Acorda Therapeutics
ACOR
+$22.7M

Sector Composition

Rank Sector Weight
1 Healthcare 81.09%
2 Real Estate 3.47%
3 Financials 1.31%
4 Technology 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNY icon
26
Alnylam Pharmaceuticals
ALNY
$27.4B
$22.6M 0.81%
281,474
+177,979
+172% +$19.8M
ENDP
27
DELISTED
Endo International plc
ENDP
$22.2M 0.8%
320,321
-5,552
-2% -$444K
MDRX
28
DELISTED
Veradigm Inc. Common Stock
MDRX
$22.1M 0.79%
1,778,200
– –
A icon
29
Agilent Technologies
A
$39.2B
$21.8M 0.78%
+635,650
New +$24.1M
VTR icon
30
Ventas
VTR
$44.7B
$20.7M 0.74%
369,266
+112,877
+44% +$7.41M
HCA icon
31
HCA Healthcare
HCA
$85.7B
$18.8M 0.68%
243,188
+29,400
+14% +$2.6M
ACAD icon
32
Acadia Pharmaceuticals
ACAD
$4.55B
$18.6M 0.67%
562,500
+192,500
+52% +$8.01M
DOC
33
DELISTED
PHYSICIANS REALTY TRUST
DOC
$18.6M 0.67%
1,230,772
+179,870
+17% +$2.76M
IBB icon
34
iShares Biotechnology ETF
IBB
$9.52B
$17.5M 0.63%
173,010
– –
MPT
35
Medical Properties Trust
MPT
$2.81B
$17.3M 0.62%
1,564,060
+410,486
+36% +$5.09M
NVO
36
Novo Nordisk
NVO
$228B
$16M 0.57%
+589,200
New +$16.7M
NBIX icon
37
Neurocrine Biosciences
NBIX
$18.7B
$15M 0.54%
375,860
– –
OHI icon
38
Omega Healthcare
OHI
$15B
$14.5M 0.52%
413,116
– –
PRTK
39
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$14.5M 0.52%
762,581
+71,581
+10% +$1.78M
ALR
40
DELISTED
Alere Inc
ALR
$14.3M 0.52%
297,901
– –
MDT icon
41
Medtronic
MDT
$110B
$13.9M 0.5%
+207,044
New +$15.2M
MCK icon
42
McKesson
MCK
$101B
$12.6M 0.45%
67,862
– –
WELL.PRI
43
DELISTED
Welltower Inc.
WELL.PRI
$12.1M 0.44%
200,000
– –
IPXL
44
DELISTED
Impax Laboratories, Inc.
IPXL
$12.1M 0.44%
344,683
– –
SYK icon
45
Stryker
SYK
$133B
$11.7M 0.42%
123,940
– –
ARDX icon
46
Ardelyx
ARDX
$1.25B
$11.1M 0.4%
+640,270
New +$12M
GSK icon
47
GSK
GSK
$104B
$11M 0.39%
+228,000
New +$11.9M
DHC
48
Diversified Healthcare Trust
DHC
$2.17B
$10.9M 0.39%
676,539
+192,619
+40% +$3.18M
SBRA icon
49
Sabra Healthcare REIT
SBRA
$5.38B
$10.6M 0.38%
456,190
– –
TMO icon
50
Thermo Fisher Scientific
TMO
$214B
$10.6M 0.38%
86,395
– –
1
2
3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2015 Portfolio in Review

As of Q3 2015, Tekla Capital Management held 179 positions worth $2.78B, up 0.66% from $2.76B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Tekla Capital Management deployed $443M of net new capital in Q3 2015, opening 61 new positions and adding to 32 existing holdings. Its largest new stake was UnitedHealth: 312,600 shares worth $36.3M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 84% a quarter earlier, followed by Real Estate and Financials.

On the sell side, the largest reduction was Amgen, an estimated $27.7M trimmed.

  • Tekla Capital Management's largest Q3 2015 buy was UnitedHealth: 312,600 shares worth $36.3M.
  • Tekla Capital Management added most to Biogen in Q3 2015, an estimated $37.6M increase.
  • Tekla Capital Management's biggest Q3 2015 reduction was Amgen, cutting an estimated $27.7M.
  • Tekla Capital Management fully exited CATAMARAN CORP COM STK (CDA) in Q3 2015, selling an estimated $26.5M.
  • Tekla Capital Management's ten largest holdings make up 42% of its $2.78B portfolio in Q3 2015.
  • Tekla Capital Management opened 61 new positions and closed 19 in Q3 2015.
  • Tekla Capital Management's portfolio value rose 0.66% quarter-over-quarter to $2.78B.

Based on Tekla Capital Management's 13F filing for Q3 2015, filed 13 Nov 2015.